Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).
Arantxa Horga, Rebecca Saenz, Gürdal Yilmaz, Abraham Simón-Campos, Keith Pietropaolo, William J Stubbings, Neil Collinson, Laura Ishak, Barbara Zrinscak, Bruce Belanger, Catherine Granier, Kai Lin, Aeron C Hurt, Xiao-Jian Zhou, Steffen Wildum, Janet Hammond
Future Virol 10.2217/fvl-2023-0115
摘要
摘要
Aim: This phase III study assessed the efficacy/safety/antiviral activity/pharmacokinetics of bemnifosbuvir, a novel, oral nucleotide analog to treat COVID-19. Patients & methods: Outpatient adults/adolescents with mild-to-moderate COVID-19 were randomized 2:1 to bemnifosbuvir/placebo. Time to symptom alleviation/improvement (primary outcome), risk of hospitalization/death, viral load and safety were evaluated. Results: Although the study was discontinued prematurely and did not meet its primary end point, bemnifosbuvir treatment resulted in fewer hospitalizations (71% relative risk reduction), COVID-19-related medically attended hospital visits, and COVID-19-related complications compared with placebo. No reduction in viral load was observed. The proportion of patients with adverse events was similar; no deaths occurred. Conclusion: Bemnifosbuvir showed hospitalization reduction in patients with variable disease progression risk and was well tolerated. Clinical Trial Registration: NCT04889040 (ClinicalTrials.gov).
KM 提取结果
0 个 Figure · 0 个 KM 面板